AD Combination Therapy Trial: Anti-Aβ + Anti-Tau

SUMMARY

# AD Combination Therapy Trial: Anti-Aβ + Anti-Tau ## Background and Rationale Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles, leading to progressive neurodegeneration. While monotherapy approaches targeting individual pathways have shown limited clinical success, emerging evidence suggests that combination therapies addressing multiple pathological mechanisms simultaneously may offer superior therapeutic ef

METHODOLOGY NOTES

Phase 1: Cell Culture Preparation - Maintain SH-SY5Y, HEK293-tau, and primary human cortical neurons in standard media. Differentiate SH-SY5Y cells using retinoic acid for 7 days (n=24 wells per condition). Phase 2: Pathological Induction - Treat cells with 5μM Aβ1-42 oligomers for 24h to induce amyloid pathology. Transfect tau-overexpression plasmids (P301L mutant) using Lipofectamine 3000. Phase 3: Treatment Administration - Apply treatments: Vehicle control, anti-Aβ antibody alone (10μg/ml), tau inhibitor alone (LMTX, 1μM), or combination therapy. Incubate for 48h with treatments refreshed every 24h. Phase 4: Endpoint Analyses - Collect samples at 24h, 48h, and 72h timepoints. Perform immunofluorescence staining for Aβ (6E10 antibody), phosphorylated tau (AT8, PHF1), and synaptic markers (synaptophysin, PSD95). Conduct Western blotting for quantitative protein analysis. Measure ATP levels using CellTiter-Glo assay. Assess cell viability via MTT assay and LDH release. Phase 5: Data A